10-Q: Elicio Therapeutics Q3 2025: Losses Narrow, Cash Dwindles

Elicio Therapeutics reports reduced net losses in Q3 2025 but faces substantial doubt about its ability to continue as a going concern due to dwindling cash reserves.

Summary

• Net loss for the three months ended September 30, 2025, was $10.1 million, a significant decrease from $18.8 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $31.9 million, down from $37.9 million for the nine months ended September 30, 2024.
• Cash and cash equivalents stood at $20.6 million as of September 30, 2025.
• The accumulated deficit reached $226.0 million as of September 30, 2025.
• Management believes current cash on hand will fund operations only through the second quarter of 2026.
• Research and development expenses decreased by $2.2 million (30%) for Q3 2025 and $3.1 million (14%) for the nine months, primarily due to patients progressing through the Phase 2 study of ELI-002 7P.
• General and administrative expenses decreased by $0.1 million (4%) for Q3 2025 but increased by $0.5 million (6%) for the nine months, mainly due to external costs associated with the January 2025 Offering and June 2025 Promissory Note Financing.
• The Independent Data Monitoring Committee (IDMC) recommended the Phase 2 AMPLIFY-7P study in mKRAS-driven PDAC continue to final analysis without modifications, confirming a favorable safety profile for ELI-002 7P.

Sentiment

Score: 3

Explanation: While the company reported reduced net losses and positive clinical trial progress (IDMC recommendation for AMPLIFY-7P continuation), the explicit 'substantial doubt about our ability to continue as a going concern' and a short cash runway (through Q2 2026) indicate severe financial challenges and high uncertainty for future operations.

Positives

• Net loss significantly decreased for both the three months ($10.1 million vs. $18.8 million) and nine months ($31.9 million vs. $37.9 million) ended September 30, 2025, compared to the prior year periods.
• The Independent Data Monitoring Committee (IDMC) recommended the Phase 2 AMPLIFY-7P study continue to final analysis without modifications and confirmed a favorable safety profile for ELI-002 7P.
• Net cash provided by financing activities for the nine months ended September 30, 2025, was $31.8 million, stemming from at-the-market offerings, the January 2025 Offering, the June 2025 Promissory Note Financing, and warrant/option exercises.
• The conversion of a $20.0 million Senior Secured Convertible Promissory Note, plus $0.3 million in accrued interest, into 3,500,573 shares of common stock in March 2025 reduced the company's debt obligations.

Negatives

• The company has experienced net losses and negative cash flows from operating activities since inception, resulting in an accumulated deficit of $226.0 million as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, as current cash and cash equivalents of $20.6 million are only expected to fund operations through the second quarter of 2026.
• Operating expenses remain high, totaling $8.0 million for the three months and $28.9 million for the nine months ended September 30, 2025.
• A change in the fair value of warrant liabilities resulted in an expense of $1.8 million for the three months and $3.2 million for the nine months ended September 30, 2025.

Risks

• Inability to obtain the necessary funding to advance the development of ELI-002 7P and other product candidates, which raises substantial doubt about the company's ability to continue as a going concern.
• Uncertainty regarding the ability of clinical trials to demonstrate the safety and efficacy of product candidates and achieve positive results.
• Reliance on third parties to conduct additional clinical trials and for the manufacture of product candidates for clinical trials.
• Potential for significant delays in enrollment in clinical trials or requirements from regulatory authorities to conduct preclinical and clinical studies beyond current expectations.
• Exposure to litigation in connection with products under development and operations, which could result in substantial costs and diversion of management resources.
• Impact of global economic and political developments, including ongoing conflicts (Ukraine/Russia, Middle East), geopolitical tensions with China, and macroeconomic conditions (tariffs, inflation, interest rate volatility, potential for economic slowdown or recession, governmental shutdowns) on business operations, clinical trials, or financial condition.
• Uncertainty regarding the company's intellectual property position, including the scope of protection, validity of third-party rights, and ability to avoid infringement.
• Inability to raise additional capital when and as needed or on favorable terms, which could lead to delays, reductions, or termination of product development or commercialization efforts.

Future Outlook

Elicio Therapeutics expects operating losses and negative operating cash flows to continue for the foreseeable future, anticipating substantial expenditures for product candidate development and requiring additional financing. The company projects its current cash on hand will fund operations only through the second quarter of 2026. Expenses are expected to increase as the lead product candidate, ELI-002 7P, advances to late-stage clinical trials, preclinical programs move to clinical trials, the pipeline expands, and regulatory approvals are sought. The final disease-free survival analysis for the Phase 2 AMPLIFY-7P study is anticipated in the first half of 2026.

Management Comments

• "We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway."
• "As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations through the second quarter of 2026 based on our current financial operating plan."
• "We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development."
• "We plan to address this condition through the sale of common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all."

Industry Context

Elicio Therapeutics operates in the highly competitive clinical-stage biotechnology sector, specializing in immunotherapies for cancer. The company's proprietary Amphiphile (AMP) technology, designed to target lymph nodes for robust T cell responses, aligns with the industry's growing focus on T cell-mediated cancer immunotherapies. By developing 'off-the-shelf' therapeutic options targeting common neoantigens like mutant KRAS, Elicio aims to address unmet needs in cancer treatment, potentially offering advantages over personalized approaches in terms of manufacturing timelines and costs. The focus on mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) and other mutant-driven cancers positions the company in areas with significant patient populations and high unmet medical needs.

Corporate Governance

Legal Proceedings

• The company does not believe it is currently a party to any claim, proceeding, or litigation the outcome of which would individually or in the aggregate be reasonably expected to have a material adverse effect on its business.

Related Party Transactions

• In March 2024, the company entered into a subscription agreement with GKCC, LLC (an entity controlled by a board member), for the issuance and sale of March 2024 Pre-Funded Warrants, generating approximately $6.0 million in net proceeds.
• In July 2024, Yekaterina Chudnovsky (a board member) and Jay Venkatesan (a board member) and trusts affiliated with Jay Venkatesan purchased July 2024 Pre-Funded Warrants and accompanying July 2024 Common Warrants as part of the Public Offering.
• In August 2024, the company entered into a securities purchase agreement with GKCC, LLC, issuing a $20.0 million Senior Secured Convertible Promissory Note, which was subsequently converted into 3,500,573 shares of common stock in March 2025.
• In June 2025, the company entered into a note purchase agreement with GKCC, LLC, issuing a $10.0 million Senior Secured Promissory Note and a warrant to purchase 103,225 shares of common stock.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity offerings and a high risk of substantial loss if the company fails to secure additional funding and cannot continue as a going concern.
• Employees' job security and stock-based compensation are contingent on the company's ability to secure additional funding and maintain operations.
• Creditors, particularly GKCC, LLC, have provided substantial debt financing and hold secured notes, indicating a vested interest in the company's financial stability and potential for repayment or conversion to equity.
• Patients relying on the development of ELI-002 7P and other product candidates for new immunotherapies face the risk that development could be halted if the company fails to secure necessary funding.

Next Steps

• Advance the lead product candidate, ELI-002 7P, to late-stage clinical trials.
• Advance preclinical programs, including ELI-007 and ELI-008, to clinical trials.
• Expand the pipeline of product candidates.
• Seek regulatory approval for investigational medicines.
• Maintain, expand, protect, and defend the intellectual property portfolio.
• Acquire or in-license technology.
• Expand clinical, scientific, management, and administrative teams.
• Operate as a public company, incurring associated costs.
• Obtain additional financing to fund operations beyond the second quarter of 2026.
• Anticipate the final disease-free survival analysis for the Phase 2 AMPLIFY-7P study in the first half of 2026.

Key Dates

Recommendation

Despite some positive clinical trial news (IDMC recommendation for AMPLIFY-7P continuation), the explicit 'substantial doubt about our ability to continue as a going concern' and a very short cash runway (through Q2 2026) present an extremely high level of financial risk. The company's reliance on future capital raises, which are not assured, makes the stock highly speculative and vulnerable to significant downside. Investors should be extremely cautious given the severe liquidity concerns.

Keywords

Elicio Therapeutics, ELTX, biotechnology, immunotherapy, cancer, clinical-stage, ELI-002 7P, mKRAS, pancreatic cancer, AMPLIFY-7P, oncology, drug development, clinical trials, financial results, SEC filing, 10-Q, cash runway, going concern, warrants, debt financing, equity offering